• von Willebrand factor (VWF) function is shear stress dependent.
Essentials
• von Willebrand factor (VWF) function is shear stress dependent.
• Platelet accumulation in a microfluidic assay correlates with VWF levels.
• The microfluidic assay discriminates type 1 von Willebrand disease from healthy controls.
• The microfluidic flow assay detects responses to therapeutic intervention (DDAVP).
Summary. Background: von Willebrand disease (VWD) is a mucocutaneous bleeding disorder with a reported prevalence of 1 in 10 000. von Willebrand factor (VWF) function and platelet adhesion are regulated by hemodynamic forces that are not integrated into most current clinical assays. Objective: We evaluated whether a custom microfluidic flow assay (MFA) can screen for deficiencies in VWF in patients presenting with mucocutaneous bleeding. Methods: Whole blood from individuals with mucocutaneous bleeding was assayed in a custom MFA. Results: Thirty-two patients with type 1 VWD (10/32) or reported mucocutaneous bleeding were enrolled. The platelet adhesion velocity (r = 0.5978 for 750 s À1 and 0.6895 for 1500 s
À1
) and the maximum platelet surface area coverage (r = is an inherited bleeding disorder with a symptomatic prevalence of 1 in 10 000 individuals [1] . Both quantitative and qualitative deficiencies of von Willebrand factor (VWF) predispose individuals to mucocutaneous bleeding [1] . The most common form of the disease is type 1, which is characterized by a mild to moderate deficiency of VWF, and shows variable expressivity and incomplete penetrance [2] [3] [4] . There is also a substantial proportion of individuals with low VWF levels who do not meet the criteria for VWD but have clinically significant mucocutaneous bleeding [5] . A third category of patients presents with mucocutaneous bleeding with no abnormal laboratory findings, including normal VWF levels, and we refer to this group as having mucocutaneous bleeding of unknown explanation (MCBUE). In each of these disorders, standard clinical assays of VWF function are unable to predict clinical bleeding [6] [7] [8] .
VWF function is regulated by the forces imposed on it by blood flow [9] . Thus, it has been hypothesized that assays that mimic physiologic hydrodynamic forces could be a more sensitive measure of VWF function than current clinical assays [10] . In this study, we tested this hypothesis by using a custom microfluidic flow assay (MFA) and the PFA-100 in individuals with VWD, low VWF levels, or MCBUE.
VWF function relies on shear and extensional stresses to expose its A1 domain [11] , which, in turn, supports platelet adhesion and aggregation through glycoprotein (GP) 1ba [12] . However, these stresses are not incorporated in most VWF assays. In the VWF ristocetin cofactor (VWF:RCo) assay, ristocetin 'activates' VWF in the absence of shear stress [13] . The VWF collagen-binding (VWF:CB) assay measures the ability of VWF to bind to collagen under static conditions [14, 15] , but it is unclear whether VWF:CB correlates with clinical bleeding [15, 16] . The PFA-100 is the most widely used flow-dependent assay of VWF and platelet function in the clinical setting. In a retrospective study of > 4000 patients, including 213 VWD cases, the PFA-100 outperformed standard VWF: RCo assays in screening for VWF deficiency [17] . However, the system is sensitive to other factors affecting platelet adhesion, such as platelet count, hematocrit, and antiplatelet agents. There are conflicting reports regarding its sensitivity/specificity for screening or confirming the diagnosis of type 1 VWD as compared with other mucocutaneous bleeding disorders [8, 17] . In addition, the PFA-100 has a relatively limited linear correlation with VWF levels in individuals with VWD, and does not output realtime platelet adhesion values [18, 19] .
Flow-based assays can incorporate the hydrodynamic forces that regulate VWF function and platelet adhesion in vivo [20, 21] . Microfluidic formats of these assays are particularly attractive for the clinical setting, owing to their low blood volume requirements and high throughput [20, 22] . Specifically for VWD, early studies in annular or parallel-plate flow chambers to assess VWD showed that platelet adhesion is dependent on VWF levels and shear rate [21, [23] [24] [25] [26] . These experiments provide an essential framework for investigating the force-dependent function of VWF in VWD, but are limited by relatively small patient numbers and the inability to monitor real-time platelet adhesion rates. More recently, Nogami et al. used a commercial microfluidic flow system (T-TAS) to study the bleeding severity of type 1 VWD patients [27] . They reported differences across the patient cohort when they used a collagen-coated microfluidic chip, but, similarly to what occurs with the PFA-100, many patients with VWF: RCo < 10 fell outside the sensitive range of the assay.
We hypothesized that a collagen-based MFA that allows for the real-time evaluation of platelet adhesion and aggregation would correlate with VWF levels in a cohort of individuals with type 1 VWD, low VWF levels, and MCBUE. We also hypothesized that the device would be useful for differentiating those with different clinical diagnoses, and that the results would correlate with clinical bleeding phenotypes as measured with a standardized bleeding assessment tool.
Materials and methods

Materials
Type I collagen, ristocetin and ADP were from ChronoLog (Havertown, PA, USA). Platelet aggregation was performed on a Chrono-Log Model 700 (Chrono-Log) or a PAP-8E Platelet Aggregometer (Bio/Data Corporation, Horsham, PA, USA [29] .
VWF:GP1bR assay (VWF functional assay)
VWF:GP1bR levels were assessed with an ILEX/Instrumentation Laboratory HemosIL Latex enhanced immunoassay, according to the manufacturer's instructions [30] .
VWF:CB assay VWF binding to type III collagen was determined with a modified ELISA based on Flood et al. [14] . A 96-well plate was coated with 5 lg mL À1 type III human placental collagen, and then blocked for 1 h with 1% BSA. Samples were incubated for 1 h at room temperature and washed with phosphate-buffered saline-Tween. VWF was detected with a rabbit anti-human VWF antibody and an HRP-conjugated goat anti-rabbit antibody. Concentrations were calculated by comparing samples with a known range of pooled normal plasma (PNP) dilutions on the same 96-well plate, where the VWF concentration of undiluted PNP was assumed to be 1 U mL À1 . VWF:CB ratios were determined by dividing the VWF:CB result by the VWF:Ag result of the same sample.
Platelet aggregation
Platelet aggregation in response to collagen (1 lg mL
À1
and 5 lg mL ), ristocetin (1 mg mL
) and ADP (10 lM) was determined. Platelet aggregation profiles were used to screen individuals for platelet dysfunction. Patients with abnormal platelet aggregometry findings were then excluded from further analysis. Platelet dysfunction was defined as < 50% of control sample aggregation in response to a minimum of two agonists, excluding ristocetin.
MFA
Type I collagen (Chronolog) (500 lg L À1 ) was patterned into a 250-lm-wide strip by use of a microfluidic channel vacuum-bonded to a glass slide, incubated for 1 h at 30°C, and then stored at 4°C up to 3 days [31, 32] . A vacuum-bonded microfluidic flow chamber was used according to previous reports [33] , and consists of three channels with a width of 500 lm, a height of 50 lm, and a length of 11 mm. Prior to use, citrated whole blood was incubated at 37°C for 15 min [34] , and was then recalcified to 7.50 mM CaCl 2 and 3.75 mM MgCl 2 . Samples were perfused at wall shear rates of 150, 750 and 1500 s À1 for 5 min with a syringe pump (Harvard Apparatus; PhD 2000, Holliston, MA, USA). Platelet accumulation was captured by relief contrast microscopy (Olympus IX81, Center Valley, PA, USA, 9 20, numerical aperture, 0.45) at 20 frames min À1 . After perfusion, the channel was rinsed with HBS and fixed with glutaraldehyde (2%) for 5 min. The total run time for each sample was 25 min from collection to fixation. Images were analyzed with a custom Sobel-based MATLAB edge-finding protocol, which quantifies the surface area coverage of platelets (Matlab File Exchange: EdgeFindRoutine). The lag time was defined as the time required to achieve 5% platelet surface coverage. The velocity was defined with the MATLAB robust fit line function (RANSAC) between achievement of the lag time and 90% of the maximum value. If a given sample did not reach 5% surface coverage (n = 4), the slope was taken from 2% coverage to 90% of the maximum. The maximum was defined as the greatest surface coverage during the assay.
PFA-100
Citrated whole blood was assayed in the PFA-100 collagen/epinephrine and collagen/ADP cartridges according to the manufacturer's instructions (Siemens Medical Solutions, Malvern, PA, USA).
Statistical analysis
Statistical analysis was performed with GRAPHPAD PRISM 7 (GraphPad, La Jolla, CA, USA). For demographic data, significance was determined with a one-way ANOVA comparing all groups. For continuous variables, significance was determined with the Spearman correlation coefficient or Pearson's correlation test. The Kruskal-Wallis test with Dunn's post hoc test was used to compare cohorts. For pre-DDAVP-post-DDAVP analysis, the one-tailed matched Wilcoxon rank test was used to determine significance under the hypothesis that DDAVP will result in a gain of function in the MFA. An a-value of < 0.05 was considered to indicate significance. Correlations of MFA outputs (lag time, velocity, and maximum) with VWF:Ag, VWF:RCo, VWF:CB and bleeding score (BS) were a predefined anaylsis, and cohort analysis was determined as a post-hoc analysis.
Results
Patient enrollment and characterization
Thirty-five patients with VWD, low VWF or MCBUE were enrolled and evaluated. Three samples were identified as being consistent with a platelet dysfunction disorder, and were excluded from further analysis. On the basis of VWF:Ag, 10 of 32 patients had type 1 VWD, 12 of 32 were patients with low VWF, and 10 of 32 were patients with MCBUE. Table 1 shows the characteristics for each cohort. There was a statistically significant difference in VWF:Ag and VWF:GP1bR between the cohorts, as expected, owing to the a priori classification of these patients. There was also a statistically significant difference in clinical BAT score among the three groups (P = 0.0083). Collagen type III-binding results demonstrated a slight decrease in the VWF:CBIII/VWF:Ag ratio in the type 1 VWD cohort as compared with the other groups, but the difference was not statistically significant. , and correlation with VWF assays and BS Figure 2 shows representative surface coverage traces for platelets on type I collagen and images from five sample types: control, low VWF before and after treatment with DDAVP, and varying levels of type 1 VWD (see Videos S1-S5). We used the lag time, velocity and maximum to characterize the dynamics of platelet accumulation. In preliminary studies (not shown), we found that saturating the surface with collagen fibers provided larger differences in platelet adhesion at low VWF levels. We therefore used a higher collagen concentration (500 lg mL
À1
) than is typical in platelet adhesion flow assays (100 lg mL À1 ) [34] . These metrics were correlated against VWF:Ag (Fig. 3) and VWF:GP1bR (Fig. S1) significant correlation between the MFA metrics and bleeding score as measured by the BAT (Fig. S2) or VWF:CBIII (Fig. S3) . Recasting the MFA data in terms of clinical groups showed that velocity and maximum metrics were particularly sensitive to shear rate in the type 1 VWD and low-VWF groups (Fig. S4 ). In the type 1 VWD group and the low-VWF group, there were significant decreases in velocity and maximum at 750 s À1 and 1500 s À1 as compared with 150 s À1 . This result suggests that, in individuals with lower VWF levels (type 1 VWD and low VWF), platelet accumulation velocities and maximal platelet accumulation are impaired as compared with individuals with higher VWF levels.
MFA metrics and PFA-100 correlation with VWF:Ag at levels < 20 IU dL
Closure times in the PFA-100 in both collagen/ADP and collagen/EPI cartridges correlated with VWF:Ag levels (Fig. 4 ). For VWF:Ag < 20 IU dL -1 , neither the PFA-100 nor the MFA metrics showed a statistically significant correlation with VWF:Ag levels, but there was a trend for better linear sensitivity in the range of VWF:Ag levels from 5 IU dL À1 to 20 IU dL À1 for the MFA than for the PFA-100 (Fig. S5) . The MFA maxima at 750 s À1 and 1500 s À1 had an increasing trend with increasing VWF:
Ag levels over this range. The closure time for PFA-100 collagen/ADP and collagen/EPI cartridges reached or was close to its maximum value (300 s) with VWF: Ag < 20 IU dL À1 .
Discriminatory power of MFA metrics and the PFA-100 on clinical diagnoses Figure 5 recasts the data in terms of clinical groups. As there was little correlation between VWF:Ag and MFA metrics at 150 s À1 , we present the data for 750 s À1 and 1500 s
. Similarly, there was no statistically significant difference in lag time. However, at these shear rates, the type 1 VWD group had significantly decreased velocities and maxima as compared with the control and MCBUE groups. Similarly, the PFA-100 had significantly higher closure times in the type 1 VWD and , a maximum metric of < 0.188 gave a sensitivity of 88.89% (95% CI 51.75-99.72) and a specificity of 80.95% (95% CI 58.09-94.55%) for type 1 VWD. Receiver operating characteristic curves are shown in Fig. S6 .
MFA metrics in response to DDAVP therapy
The MFA metrics were evaluated for six patients treated with DDAVP. Paired analyses were performed on blood drawn immediately prior to, and 1 h after, administration of intranasal DDAVP (150 lg for individuals < 50 kg, and 300 lg for individuals > 50 kg) (Fig. 6 ). At 750 s À1 , the lag time decreased but the velocity and maximum did not increase. At 1500 s À1 , the lag time, maximum and velocity all significantly improved. There were no statistically significant changes in MFA metrics at 150 s À1 before or after DDAVP administration. These results mirrored similar increases in VWF:Ag and VWF:GP1bR seen before and after DDAVP administration (data not shown); one patient with MCBUE did not respond clinically to DDAVP, and for that patient the MFA did not show an increase in function.
Discussion
The force dependence of VWF function and its interactions with platelets has led to the hypothesis that measuring VWF-dependent platelet function under flow conditions will provide additional information beyond that provided by existing clinical assays. In this study, we tested this hypothesis by using a custom microfluidic chamber in a cohort of individuals with type 1 VWD, low VWF, and MCBUE. Our cohort of individuals was focused on patients presenting symptoms of mucocutaneous bleeding with and without low VWF levels. We have previously demonstrated that a collagen-coated MFA correlates with VWF levels in healthy controls [33] , and we sought to extend this analysis to individuals with bleeding symptoms with a specific focus on individuals with lower VWF levels. Although there remains controversy over the classification of patients with type 1 VWD versus low VWF levels, our categories are based on the most recent NHLBI guidelines and the observation that the majority of individuals with VWF levels < 30 IU dL À1 have mutations in VWF, but the majority of individuals with VWF levels > 40 IU dL À1 do not [35, 36] . In our cohort, the lack of statistically significant changes in collagen-induced (1 lg mL À1 ) and ADP-induced (10 lM) aggregation suggests that our results are probably attributable to variability in VWF quantity/function as opposed to intrinsic platelet function. Collagen binding among those in the type 1 VWD, low-VWF and MCBUE cohorts was slightly lower than in controls, similarly to what has been previously reported [14] . Our data also demonstrated that individuals with type 1 VWD had higher BSs, consistent with previous studies [28] . In terms of MFA-based metrics, we demonstrate that the lag time to 5% platelet surface area coverage, the platelet adhesion velocity of the linear portion of the platelet accumulation curve and the maximum platelet surface area coverage are strongly correlated with VWF: Ag and VWF:GP1bR levels at shear rates of 750 s
À1
and 1500 s
. This, in conjunction with our earlier publication [33] , suggests that a collagen-based MFA is sensitive to a wide range of VWF levels, both in individuals with bleeding and in healthy controls. There was no significant correlation at 150 s À1 , suggesting that, at this shear rate, platelet accumulation is not strongly dependent on VWF levels. The strong correlative findings in our MFA are similar to those of the PFA-100, whereby PFA-100 closure time was also correlated with VWF:Ag and VWF:GP1bR levels. Future investigation of other shear rates and/or prothrombotic surfaces may provide better differentiation between VWF quantity/ function.
In contrast to the correlation with VWF:Ag and VWF: GP1bR levels, our MFA metrics did not correlate with VWF:CBIII/VWF:Ag ratios, suggesting that our MFA metrics were not sensitive to changes in VWF:CB function. This implies that our assay more accurately reflects the platelet-binding function of VWF than its collagenbinding function. This may be attributable to the relatively high amount of immobilized type 1 collagen used in this study. MFA metrics did not correlate with BSs. Recent studies by Ogiwara et al. and Nogami et al. used a microfluidic-based approach that monitored pressure gradients to assess thrombus formation, and observed variations among individuals with different BSs, and differentiated high from low BSs on the basis of their thrombus time in collagen/thromboplastin-based devices; however, this difference was seen only in individuals with VWF:RCo < 10 [27, 37] . The correlation with BSs in the Nogami study was primarily in a group of 25 individuals with VWF: RCo levels of < 10; in our study, we were able to enroll only seven individuals who met this criterion. The relatively small subgroup in our analysis probably limited the finding of statistical significance in this cohort.
From a categorical perspective, we investigated whether our MFA could reliably differentiate clinical subgroups.
Both the platelet adhesion velocity and the maximum platelet adhesion at 750 s À1 and 1500 s À1 could discriminate type 1 VWD patients from the control and MCBUE cohorts; this is probably because of the significant correlation of these metrics with VWF levels. The discriminative power of the PFA-100 was similar; the PFA-100 was also able to differentiate between the low-VWF and control cohorts. These data suggest that force-dependent assays, and specifically a collagen-based MFA device, have both correlative and discriminative power in the estimation of VWF levels and the screening of VWD. The MFA detected responses to DDAVP therapy. We demonstrated that an MFA, requiring only 250 lL of blood, showed a universal response to therapy at 1500 s
. Our results are consistent with previous reports demonstrating that DDAVP can improve platelet adhesion, bleeding times and PFA-100 closure time in patients with type 1 VWD [26] . Our data support the sensitivity of flow-based models to VWF function at high shear stresses, and suggest the potential use of these assays to model therapeutic response. Additionally, we showed that improvement in VWF function following DDAVP administration was consistently determined only at high shear rates (1500 s
). Previous investigations at low shear rates (50-350 s À1 ) with collagen-coated glass devices or denuded endothelium have demonstrated that there are minimal differences in platelet adhesion between VWD patients and controls [21, 23] . At higher shear rates (> 1000 s À1 ), some investigations have demonstrated minimal to no significant differences in collagen-based platelet adhesion in VWD [21, 23] , whereas other studies have clearly demonstrated a forcedependent decrease in platelet adhesion [26, 38, 39] . Our data are consistent with previous observations, when, at 150 s À1 , there was no difference between clinical cohorts and no significant correlation with VWF levels, but at 750 s À1 and 1500 s À1 there was a clear decrease in platelet adhesion velocity and maximal platelet adhesion in individuals with type 1 VWD. We also investigated two additional cohorts, those with low VWF and those with MCBUE. A decrease in platelet adhesion at high shear rates was observed in individuals with low VWF, but not in individuals with MCBUE. This is probably becuase of the strong dependence of our MFA metrics on VWF levels. There are several limitations of this study. Our MFA metrics were correlated with VWF levels across a broad range of values; however, our MFA metrics were not able to predict a clinical subgroup for each patient. Our cohort size was potentially too small to have sufficient statistical power to discriminate clinical subgroups, and we specifically did not have many patients with VWF < 30 IU dL À1 , which was our inclusion criterion for type 1 VWD. Many of our patients with MCBUE were enrolled on the basis of their presenting complaint; however, upon further standardized evaluation, the severity of their bleeding varied significantly. From an assay perspective, the conditions for MFAs are not optimized for linear sensitivity to VWF level and function, but we generally followed the recommendations of the ISTH Subcommittee on Global Assay recommendations [10, 40] . Nevertheless, variations in channel cross-sectional area, height/width ratios, shear rates, anticoagulant and collagen type can affect platelet adhesion. Although our data are consistent with VWF having a strong effect on platelet adhesion, there are probably multiple other factors that affect in vitro and in vivo platelet adhesion, including collagen and platelet receptor densities, hematocrit, and variations in coagulation factor levels. Finally, our postacquisition analysis was based on a two-dimensional analysis of platelet surface area, and may have underestimated platelet deposition in the vertical plane; further study of thrombus volumes may provide additional details.
In summary, we demonstrate that, in a cohort of individuals with VWD/mucocutaneous bleeding, a collagenbased MFA correlates with VWF levels across a wide spectrum of levels, appropriately groups patients with a diagnosis of type 1 VWD, demonstrates shear-dependent abnormalities in individuals with low VWF, and accurately reflect the response of VWF levels to DDAVP. The relatively small sample size input of our assay (250 lL) and the strong ability to correlate with relevant hemostatic parameters and monitor responses to therapeutic interventions suggest the potential utility of translating microfluidic-based technology to clinical situations.
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